Medical
MicroPort MedBot, Toumai's maker, said it expected its first-ever half-year profit, of about 28 to 40 million yuan.
A dated step forward on the record · Company-reported
What the source says
“the Company expects to record an unaudited net profit of approximately RMB 28 million to RMB 40 million”
What it means
Toumai, from MicroPort MedBot (MicroPort group), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. Its stage is set by other milestones on its record; this one adds to the history. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Toumai
- A surgeon used Toumai to do ten remote weight-loss operations in one session of about 11 hours, linking IRCAD sites in Strasbourg, France and Indore, India.
- MicroPort signed a cooperation agreement built around Toumai with Korea University Anam Hospital in South Korea.
- Toumai received a CE mark in the European Union for remote surgery in urology, general surgery, chest surgery and gynecology.
- China's regulator, the NMPA, approved Toumai SP, a single-port version, for urology, general surgery and gynecology.
- Surgeons did six prostate cancer operations with Toumai in Angola, two of them remotely from another site on the same hospital campus. MicroPort said Toumai had been used in more than 200 remote operations worldwide.